Experimental cancer drug BR105 trial stopped early
NCT ID NCT05351697
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Cancer drug pralsetinib may change how the body processes other medications
- Acupuncture with a jolt: could needles shield nerves from chemo?
- Real-World check: does adding nivolumab to chemo help stomach cancer patients?
- New drug combo shows promise for tough cancers
- Cancer drug pelabresib gets Long-Term safety check in extension trial